Want to see SGMOQ full AI Analyst Report?
Sangamo Therapeutics (SGMOQ) AI Stock Analysis
Sangamo Therapeutics
(Other OTC:SGMOQ)
The score is driven down primarily by very weak financial performance (declining revenue, large losses, heavy cash burn, and negative equity) and highly adverse corporate events (Chapter 11 bankruptcy and delisting/OTC trading warnings). Technicals also reflect a broader downtrend with negative momentum, and valuation provides little support due to negative earnings and no dividend yield data.
Sangamo Therapeutics (SGMOQ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $49.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.38M
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 2.72
- Revenue Growth
- -45.80%
- EPS Growth
- -0.16%
- Country
- US
- Employees
- 142
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sangamo Therapeutics Business Overview & Revenue Model
Company Description
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage...
How the Company Makes Money
Sangamo Therapeutics primarily makes money through (1) collaboration and licensing arrangements and (2) to a lesser extent, other operating income tied to partnered programs; the company has not historically relied on product sales because its key ca...
Sangamo Therapeutics Earnings Call Summary
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Sangamo said the rolling BLA for ST‑920 is in progress with the first two modules submitted, the clinical module (1‑year data) already filed, management characterizing the filing as roughly 3/5 complete and anticipating BLA completion “as early as this summer” subject to securing additional funding; the FDA agreed accelerated approval can be based on mean annualized eGFR slope at 52 weeks across all 32 dosed patients, affirmed no additional confirmatory trial is required, and indicated 104‑week (2‑year) data across those 32 patients may be used for full approval (the last patient reached the 2‑year time point around April). Management also highlighted durability and safety — four patients beyond five years with supraphysiological alpha‑Gal and 17 patients off ERT (some >3 years) — and operational progress in neurology with six sites activated for the Phase I/II STAND (ST‑503), GLP toxicology for ST‑506 completed with analysis ongoing, and MHRA alignment on key matters.
Sangamo Therapeutics Financial Statement Overview
Summary
Very weak financial profile: declining TTM revenue (-12.6%), very large ongoing operating and net losses (TTM EBIT about -$110M; net income about -$123M), heavy and persistent cash burn (TTM operating and free cash flow about -$90M), and a major balance-sheet red flag with stockholders’ equity turning negative (about -$19M), implying elevated financing/dilution risk.
Income Statement
18Very NegativeBalance Sheet
24NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.56M | 39.55M | 57.80M | 176.23M | 111.30M | 110.70M |
| Gross Profit | 34.56M | 31.95M | 57.80M | 176.23M | 99.19M | 110.70M |
| EBITDA | -117.46M | -115.90M | -89.09M | -96.80M | -179.74M | -160.35M |
| Net Income | -123.33M | -122.93M | -97.94M | -257.83M | -192.28M | -178.29M |
Balance Sheet | ||||||
| Total Assets | 59.97M | 59.74M | 101.64M | 165.32M | 562.51M | 721.92M |
| Cash, Cash Equivalents and Short-Term Investments | 27.59M | 20.95M | 41.92M | 81.00M | 277.63M | 376.55M |
| Total Debt | 19.33M | 26.80M | 30.57M | 38.10M | 43.11M | 48.08M |
| Total Liabilities | 78.92M | 74.01M | 78.86M | 82.43M | 267.55M | 346.58M |
| Stockholders Equity | -18.95M | -14.27M | 22.77M | 82.89M | 294.96M | 375.34M |
Cash Flow | ||||||
| Free Cash Flow | -90.46M | -97.31M | -67.41M | -246.00M | -243.80M | -256.53M |
| Operating Cash Flow | -90.34M | -97.21M | -67.14M | -224.84M | -223.63M | -233.25M |
| Investing Cash Flow | -115.00K | -102.00K | 37.52M | 153.53M | 59.28M | 248.20M |
| Financing Cash Flow | 89.31M | 70.75M | 28.38M | 14.59M | 84.66M | 32.86M |
Sangamo Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMOQ, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.14, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.73 is Neutral, neither overbought nor oversold. The STOCH value of 81.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMOQ.
Sangamo Therapeutics Risk Analysis
Sangamo Therapeutics disclosed 62 risk factors in its most recent earnings report. Sangamo Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSangamo Therapeutics Peers Comparison
Overall Rating
BDTX48Neutral
CABA46Neutral
ELTX40Underperform- SGMOQ37.8Underperform
CRBU29Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BDTX | 48Neutral | $102.27M | -2.40 | -38.80% | ― | -100.00% | -392.92% |
| CABA | 46Neutral | $256.01M | -0.95 | -128.27% | ― | ― | 41.56% |
| ELTX | 40Underperform | $45.51M | -0.79 | -1266.43% | ― | ― | 49.43% |
| SGMOQ | 38Underperform | $48.06M | -0.20 | 6686.36% | ― | -45.80% | -0.16% |
| CRBU | 29Underperform | $45.37M | -0.39 | -89.11% | ― | 10.02% | 39.66% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SGMOQ | Sangamo Therapeutics, Inc. | 0.12 | -0.46 | -79.93% | |
| CABA | Cabaletta Bio, Inc. | 1.51 | -1.50 | -49.83% | |
| BDTX | Black Diamond Therapeutics, Inc. | 1.78 | -2.17 | -54.94% | |
| ELTX | Elicio Therapeutics, Inc | 1.68 | -7.57 | -81.84% | |
| CRBU | Caribou Biosciences, Inc. | 0.42 | -2.01 | -82.59% |
Sangamo Therapeutics Corporate Events
Sangamo Therapeutics Updates Chapter 11 Operating Reports
NegativeOn June 23, 2026, Sangamo Therapeutics filed for Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware, beginning a reorganization process that has left the company operating under court supervision. On October 23, 2026, it...
Sangamo Therapeutics Highlights Risks Amid Ongoing Bankruptcy
NegativeOn June 23, 2026, Sangamo Therapeutics filed for Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware, and on October 14, 2026 it submitted a monthly operating report covering the period from August 1 to August 31, 2026. Th...
Sangamo Therapeutics Completes Fabry Gene Therapy Asset Sale
NegativeOn June 23, 2026, Sangamo Therapeutics, Inc. filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the District of Delaware and has since operated as a debtor-in-possession under court supervision. Following a bid proce...
Sangamo Therapeutics Completes Key Technology Asset Sale
NegativeOn September 4, 2026, Sangamo Therapeutics completed the court-approved sale of substantially all of its key technology platforms and related intellectual property to Eli Lilly and Company for $50 million in cash and the assumption of certain liabili...
Sangamo Therapeutics Signs Asset Sale Deal Amid Bankruptcy
NegativeOn June 23, 2026, Sangamo Therapeutics filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware, launching a court-supervised restructuring process. As part of this process, the company ran a Section 363 au...
Sangamo Concludes Section 363 Asset Sales in Bankruptcy
NegativeOn August 13, 2026, Sangamo Therapeutics, which filed for Chapter 11 protection on June 23, 2026, announced that it had completed a court-supervised Section 363 auction of key assets, selecting winning bids from PTC Therapeutics, Eli Lilly and other...
Sangamo Therapeutics Reports Post-Bankruptcy Operating Developments
NegativeAs of June 23, 2026, Sangamo Therapeutics filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware, and on August 6, 2026 it submitted its monthly operating report covering June 2026. During this...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026